Check out this morning’s top movers from around Wall Street, compiled by The Fly.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
HIGHER –
- Marinus Pharmaceuticals (MRNS) up 43% after Immedica Pharma and the company announced that they have entered into an agreement and plan of merger under which Immedica has agreed to acquire Marinus for 55c per share
- Maiden Holdings (MHLD) up 8% after the company and Kestrel Group announced that they have entered into a combination agreement to combine and form a new, publicly listed specialty program group
- Vera Bradley (VRA) up 8% after the company’s largest shareholder, Fund 1, said it believes that a strategic or financial buyer would be able to complete a transaction at an attractive premium for shareholders
- Safe Pro (SPAI) up 2% after announcing that it has received an official request from Ukraine’s State Special Transport Service to secure $5M for the purchase up to 50 Safe Pro AI Powered Drone Demining packages
- Foresight Autonomous (FRSX) up 2% after signing a commercial cooperation agreement with Konec
LOWER –
- Axsome Therapeutics (AXSM) down 7% after announcing the results of the ACCORD-2, ADVANCE-2, and long-term safety trials in the Alzheimer’s disease agitation indication
- Boeing (BA) down 3% after the Jeju Air 737-800 crash in South Korea, which killed 179 people
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRNS:
- Marinus Ends Agreements Amid Strategic Review
- Marinus Pharmaceuticals Merges with Immedica Pharma AB
- Marinus Pharmaceuticals to be acquired by Immedica for 55c per share
- Marinus Unveils Management Retention and Severance Plans
- Marinus Pharmaceuticals Faces Financial Turmoil Amidst Class Action Lawsuit
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
